Search
Regadenoson
go.drugbank.com/drugs/DB06213ApprovedInvestigationalRegadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
Categories: Adenosine A receptor agonistsExisulind
go.drugbank.com/drugs/DB06246InvestigationalCategories: Compounds used in a research, industrial, or household settingUdenafil
go.drugbank.com/drugs/DB06267ApprovedUdenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena.
Tocilizumab
go.drugbank.com/drugs/DB06273ApprovedInvestigational[L44483] Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.[L48385]. … Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.
Senicapoc
go.drugbank.com/drugs/DB06280InvestigationalSenicapoc (ICA-17043) is a novel Gardos channel blocker.[A259068] It is being investigated for the treatment of sickle cell disease.
Sonepcizumab
go.drugbank.com/drugs/DB06305InvestigationalA humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities.